AbbVie Stock Drops 12% On Schizophrenia Drug Setback: Should You Buy The Dip?
November 11, 2024 at 15:19 PM EST
AbbVie reports disappointing mid-stage data for its schizophrenia drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
